Currently Viewing:
Newsroom
Currently Reading
Comparing Efficacy of Ozanimod on Annualized Relapse Rate With Other DMTs
October 01, 2019 – Laura Joszt
AJMC® in the Press, September 27, 2019
September 27, 2019 – AJMC Staff
No Association Between Biologics to Treat Psoriasis and Psychiatric Illness
September 26, 2019 – Laura Joszt
As Relevance of MRD Testing Grows, So Does Access
September 25, 2019 – Laura Joszt
Physician Shortage Likely to Impact OB/GYN Workforce in Coming Years
September 21, 2019 – Jaime Rosenberg
Early Levels of Ustekinumab May Predict Longer-term Response in Patients With Psoriasis
September 21, 2019 – Laura Joszt
40-Year-Old RA Drug May Be Low-Cost Option for Patients With Myeloproliferative Neoplasms
September 18, 2019 – Laura Joszt
Patient-Reported Outcomes Gain Attention at ECTRIMS 2019
September 17, 2019 – Mary Caffrey
The Potential of ctDNA as a Prognostic Biomarker in Patients With Colorectal Cancer
September 16, 2019 – Laura Joszt

Comparing Efficacy of Ozanimod on Annualized Relapse Rate With Other DMTs

Laura Joszt
Ozanimod, under development to treat relapsing-remitting multiple sclerosis (RRMS), has greater efficacy on the annualized relapse rate (ARR) than most other first-line disease-modifying therapies (DMTs), according to 2 abstracts presented at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Ozanimod, an oral, sphingosine 1-phosphate (S1P) receptor modulator under development to treat relapsing-remitting multiple sclerosis (RRMS), has greater efficacy on the annualized relapse rate (ARR) than most other first-line disease-modifying therapies (DMTs), according to 2 abstracts presented at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

In one abstract, the researchers assessed the relative efficacy in relapses and safety of the treatment compared with other DMTs available to treat RRMS.1 The authors reviewed 44 trials that included 29,568 patients with RRMS. They found that ozanimod 1.0 mg was more effective at reducing ARR than glatiramer acetate 20 mg and 40 mg; interferon β-1a 30 mcg, 22 mcg, 44 mcg, and 250 mcg; and teriflunomide 7 mg and 14 mg. Ozanimod was comparable to cladribine 3.5 mg/kg, dimethyl fumarate 240 mg, fingolimod 0.5 mg, and peg-interferon β-1a 125 mcg.

The occurrence of serious adverse events (AEs) was comparable among all treatments and ozanimod had fewer AEs occur compared with alemtuzumab 12 mg, cladribine 3.5 mg/kg, dimethyl fumarate 240 mg, glatiramer acetate 40 mg, and peg-interferon β-1a 125 mcg.

According to the authors the efficacy and safety profile supports the development of oral ozanimod to treat RRMS.

In the second abstract, the authors used a number-needed-to-treat (NNT) analysis and a risk-benefit (RB) assessment to evaluate treatment effects of ozanimod compared with other first-line DMTs. They analyzed comparative risks and benefits from clinical trials of dimethyl fumarate 240 mg, fingolimod 0.5 mg, glatiramer acetate 20 mg and 40 mg, interferon β-1a 30 mcg and 44 mcg, ozanimod 1 mg, and teriflunomide 14 mg. ARR was calculated as NNTs relative to placebo.

For ozanimod and fingolimod has the lowest NNT (4) to prevent 1 relapse during 1 year relative to placebo, followed by dimethyl fumarate 240 mg (5), glatiramer acetate 20 mg and 40 mg and interferon β-1a 44 mcg (6), teriflunomide 14 mg (7), and lastly, interferon β-1a 30 mcg.

Ozanimod had a high incremental net benefit for ARR versus AEs relative to placebo and other DMTs.

References

1. Tencer T, Snedecor SJ, Nicoloso. Systematic literature review and network meta-analysis of ozanimod compared with other treatments in relapsing-remitting multiple sclerosis. Presented at: ECTRIMS 2019, Stockholm, Sweden; September 11-13, 2019. Poster P1068.

2. Kumar J, Tencer T, Swallow E, Patterson-Lomba O, Carley C, Signorovitch J. Number-needed-to-treat analysis and risk-benefit assessment of ozanimod compared with first-line disease-modifying therapies for relapsing-remitting multiple sclerosis. Presented at: ECTRIMS 2019, Stockholm, Sweden; September 11-13, 2019. Poster EP1590.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up